INS and type 2 diabetes mellitus: To elucidate the effects of exenatide and dulaglutide on BMD in people with diabetes, a single‐blind study in overweight T2D people randomized to exenatide, dulaglutide, insulin glargine, or placebo reported a BMD increase of the total hip in the exenatide group.